Increased cortical excitability as a critical element in schizophrenia pathophysiology

Cortical Deficits in Schizophrenia: From Genes to Function

Volumn , Issue , 2008, Pages 219-236

  O'Donnell, Patricio ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905718184     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-74351-6_11     Document Type: Chapter

References (120)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin R, Seibyl J, Bowers M, van Dyck C, Charney D, Innis R, Laurelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation of a second cohort. Am J Psychiat 155:761-767.
2. Addington AM, Gornick M, Duckworth J, Sporn A, Gogtay N, Bobb A, Greenstein D, Lenane M, Gochman P, Baker N, Balkissoon R, Vakkalanka RK, Weinberger DR, Rapoport JL, Straub RE (2005) GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD (67)), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry 10:581-588.
3. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE, Jr., Jones EG (1996) Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16:19-30.
4. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580-1589.
5. Al-Amin HA, Shannon Weickert C, Weinberger DR, Lipska BK (2001) Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus. Biol Psychiatry 49:528-539.
6. Altschuler LL, Conrad A, Kovelman JA, Scheibel A (1987) Hippocampal pyramidal cell orientation in schizophrenia. Arch Gen Psychiat 44:1094-1098.
7. Anderson SA, Classey JD, Conde F, Lund JS, Lewis DA (1995) Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex. Neuroscience 67:7-22.
8. Arnold SE, Hyman BT, Van Hoesen GW, Damasio AR (1991) Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiat 48:625-632.
9. Ashe PC, Chlan-Fourney J, Juorio AV, Li XM (2002) Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus. Brain Res 956:126-135.
10. Austin CP, Ky B, Ma L, Morris JA, Shughrue PJ (2004) Expression of Disrupted-In-Schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience 124:3-10.
11. Bachevalier J, Alvarado MC, Malkova L (1999) Memory and socioemotional behavior in monkeys after hippocampal damage incurred in infancy or in adulthood. Biol Psychiat 46:329-339.
12. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran G, Rylett RJ, Neufeld RW (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 54:959-965.
13. Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24:349-355.
14. Benes FM (1997) The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. J Psychiatr Res 31:257-275.
15. Benes FM (1999) Evidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biol Psychiatry 46:589-599.
16. Berman KF, Zec RF, Weinberger DR (1986) Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort. Arch Gen Psychiat 43:126-135.
17. Brake WG, Sullivan RM, Flores G, Srivastava L, Gratton A (1999) Neonatal ventral hippocampal lesions attenuate the nucleus accumbens dopamine response to stress: an electrochemical study in the adult rat. Brain Res 831:25-32.
18. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA, Monaghan DT (1994) The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J Neurosci 14:5471-5484.
19. Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJ, Weinberger DR (2000a) Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatry 157:1646-1651.
20. Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, Goldberg TE, Weinberger DR (2000b) Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 10:1078-1092.
21. Campion D, d'Amato T, Bastard C, Laurent C, Guedj F, Jay M, Dollfus S, Thibaut F, Petit M, Gorwood P, Babron MC, Waksman G, Martinez M, Mallet J (1994) Genetic study of dopamine D1, D2, and D4 receptors in schizophrenia. Psychiat Res 51:215-230.
22. Cannon TD, van Erp TG, Bearden CE, Loewy R, Thompson P, Toga AW, Huttunen MO, Keshavan MS, Seidman LJ, Tsuang MT (2003) Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr Bull 29:653-669.
23. Carter CS, Perlstein W, Ganguli R, Brar J, Mintun M, Cohen JD (1998) Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry 155:1285-1287.
24. Chambers JS, Thomas D, Saland L, Neve RL, Perrone-Bizzozero NI (2005) Growthassociated protein 43 (GAP-43) and synaptophysin alterations in the dentate gyrus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:283-290.
25. Chambers RA, Self DW (2002) Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia. Neuropsychopharmacology 27:889-905.
26. Chambers RA, Moore J, McEvoy JP, Levin ED (1996) Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacol 15:587-594.
27. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, Egan MF, Kleinman JE, Weinberger DR (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75:807-821.
28. Christison GW, Casanova MF, Weinberger DR, Rawlings R (1989) A quantitative investigation of hippocampal pyramidal cell size, shape and variability of orientation in schizophrenia. Arch Gen Psychiat 46:1027-1032.
29. Coyle JT, Tsai G (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174:32-38.
30. Cunningham MG, Bhattacharyya S, Benes FM (2002) Amygdalo-cortical sprouting continues into early adulthood: implications for the development of normal and abnormal function during adolescence. J Comp Neurol 453:116-130.
31. Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S (2002) Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch Gen Psychiatry 59:347-354.
32. de Lima AD, Opitz T, Voigt T (2004) Irreversible loss of a subpopulation of cortical interneurons in the absence of glutamatergic network activity. Eur J Neurosci 19:2931-2943.
33. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM (1989) A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glicine. Clin Neuropharmacol 12:1-13.
34. Dunah AW, Yasuda RP, Wang YH, Luo J, Davila-Garcia M, Gbadegesin M, Vicini S, Wolfe BB (1996) Regional and ontogenic expression of the NMDA receptor subunit NR2D protein in rat brain using a subunit-specific antibody. J Neurochem 67:2335-2345.
35. Eastwood SL, Harrison PJ (1998) Hippocampal and cortical growth-associated protein-43 messenger RNA in schizophrenia. Neuroscience 86:437-448.
36. Eastwood SL, Harrison PJ (2005) Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res 73:159-172.
37. Eastwood SL, Burnet PWJ, Harrison PJ (1995) Altered synaptophisin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 66:309-319.
38. Eastwood SL, Burnet PW, Harrison PJ (2005) Decreased hippocampal expression of the susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia. Biol Psychiatry 57:702-710.
39. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, Mattay VS, Bertolino A, Hyde TM, Shannon-Weickert C, Akil M, Crook J, Vakkalanka RK, Balkissoon R, Gibbs RA, Kleinman JE, Weinberger DR (2004) Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 101:12604-12609.
40. Eichhammer P, Wiegand R, Kharraz A, Langguth B, Binder H, Hajak G (2004) Cortical excitability in neuroleptic-naive first-episode schizophrenic patients. Schizophr Res 67:253-259.
41. Flagstad P, Mork A, Glenthoj BY, van Beek J, Michael-Titus AT, Didriksen M (2004) Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology 29:2052-2064.
42. Flores G, Alquicer G, Silva-Gomez AB, Zaldivar G, Stewart J, Quirion R, Srivastava LK (2005) Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus. Neuroscience 133:463-470.
43. Gao WJ, Goldman-Rakic PS (2003) Selective modulation of excitatory and inhibitory microcircuits by dopamine. Proc Natl Acad Sci USA 100:2836-2841.
44. Glantz LA, Lewis DA (2000) Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57:65-73.
45. Gorba T, Wahle P (1999) Expression of TrkB and TrkC but not BDNF mRNA in neurochemically identified interneurons in rat visual cortex in vivo and in organotypic cultures. Eur J Neurosci 11:1179-1190.
46. Goto Y, O'Donnell P (2002) Delayed mesolimbic system alteration in a developmental animal model of schizophrenia. J Neurosci 22:9070-9077.
47. Goto Y, O'Donnell P (2004) Prefrontal lesion reverses abnormal mesoaccumbens response in an animal model of schizophrenia. Biol Psychiatry 55:172-176.
48. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24.
49. Halim ND, Weickert CS, McClintock BW, Hyde TM, Weinberger DR, Kleinman JE, Lipska BK (2003) Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development. Mol Psychiatry 8:797-810.
50. Harrison PJ (2004) The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 174:151-162.
51. Harrison PJ, Eastwood SL (1998) Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia. Lancet 352:1669-1673.
52. Harrison PJ, Weinberger DR (2004) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry.
53. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis DA (2003) Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23:6315-6326.
54. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA (2005) Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25:372-383.
55. Haydon PG (2001) GLIA: listening and talking to the synapse. Nat Rev Neurosci 2:185-193.
56. Ilyin VI, Whittemore ER, Guastella J, Weber E, Woodward RM (1996) Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol Pharmacol 50:1541-1550.
57. Jackson ME, Homayoun H, Moghaddam B (2004) NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci U S A 101:8467-8472.
58. Javitt DC, Zukin SR (1991) Recent advances in the phenciclidine model of schizophrenia. Am J Psychiat 148:1301-1308.
59. Jovanovic JN, Thomas P, Kittler JT, Smart TG, Moss SJ (2004) Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA (A) receptor phosphorylation, activity, and cell-surface stability. J Neurosci 24:522-530.
60. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 158:360-369.
61. Kato K, Shishido T, Ono M, Shishido K, Kobayashi M, Suzuki H, Nabeshima T, Furukawa H, Niwa S (2000) Effects of phencyclidine on behavior and extracellular levels of dopamine and its metabolites in neonatal ventral hippocampal damaged rats. Psychopharmacology (Berl) 150:163-169.
62. Kolomeets NS, Orlovskaya DD, Rachmanova VI, Uranova NA (2005) Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: A postmortem morphometric study. Synapse 57:47-55.
63. Kovelman JA, Scheibel AB (1984) A neurohistological correlate of schizophrenia. Biol Psychiat 19:1601-1917.
64. Kuner T, Schoepfer R (1996) Multiple structural elements determine subunit specificity of Mg2+ block in NMDA receptor channels. J Neurosci 16:3549-3558.
65. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
66. Laruelle M (2000) The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Rev 31:371-384.
67. Law AJ, Weickert CS, Hyde TM, Kleinman JE, Harrison PJ (2004a) Reduced spinophilin but not microtubule-associated protein 2 expression in the hippocampal formation in schizophrenia and mood disorders: molecular evidence for a pathology of dendritic spines. Am J Psychiatry 161:1848-1855.
68. Law AJ, Shannon Weickert C, Hyde TM, Kleinman JE, Harrison PJ (2004b) Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience 127:125-136.
69. Le Pen G, Moreau JL (2002) Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 27:1-11.
70. Lewis BL, O'Donnell P (2000) Ventral tegmental area afferents to the prefrontal cortex maintain membrane potential 'up' states in pyramidal neurons via D1 dopamine receptors. Cerebral Cortex 10:1168-1175.
71. Lewis DA, Volk DW, Hashimoto T (2004) Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174:143-150.
72. Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312-324.
73. Lewis DA, Pierri JN, Volk DW, Melchitzky DS, Woo T-UW (1999) Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiat 46:616-626.
74. Lipska B, al-Amin H, Weinberger D (1998) Excitotoxic lesions of the rat medial prefrontal cortex. Effects on abnormal behaviors associated with neonatal hippocampal damage. Neuropsychopharmacology 19:451-464.
75. Lipska BK, Weinberger DR (1994) Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 10:199-205.
76. Lipska BK, Jaskiw GE, Weinberger DR (1993) Postpuberal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocanpal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 90:67-75.
77. Lipska BK, Aultman JM, Verma A, Weinberger DR, Moghaddam B (2002) Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology 27:47-54.
78. Lipska BK, Lerman DN, Khaing ZZ, Weickert CS, Weinberger DR (2003) Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. Eur J Neurosci 18:391-402.
79. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1995) Neonatal excitotoxic hippocampal damage in rats cause post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacol 132:303-310.
80. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959) Study of a new schizophrenomimetic drug - Sernyl. Arch Neurol Psychiat 81:363-369.
81. Makino C, Shibata H, Ninomiya H, Tashiro N, Fukumaki Y (2005) Identification of singlenucleotide polymorphisms in the human N-methyl-D-aspartate receptor subunit NR2D gene, GRIN2D, and association study with schizophrenia. Psychiatr Genet 15:215-221.
82. Manoach DS (2003) Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 60:285-298.
83. Meador-Woodruff JH, Healy DJ (2000) Glutamate receptor expression in schizophrenic brain. Brain Res Rev 31:288-294.
84. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R, Weinberger DR, Berman KF (2005) Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 8:594-596.
85. Mirnics K, Middleton FA, Lewis DA, Levitt P (2001) Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci 24:479-486.
86. Mitchell CP, Grayson DR, Goldman MB (2005) Neonatal lesions of the ventral hippocampal formation alter GABA-A receptor subunit mRNA expression in adult rat frontal pole. Biol Psychiatry 57:49-55.
87. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927.
88. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, Meuth S, Nagy A, Greene RW, Nestler EJ (2004) Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A 101:10827-10832.
89. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
90. O'Donnell P, Lewis BL, Weinberger DR, Lipska BK (2002) Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cereb Cortex 12:975-982.
91. Okada M, Corfas G (2004) Neuregulin1 downregulates postsynaptic GABAA receptors at the hippocampal inhibitory synapse. Hippocampus 14:337-344.
92. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiat 52:998-1007.
93. Pantelis C, Yucel M, Wood SJ, Velakoulis D, Sun D, Berger G, Stuart GW, Yung A, Phillips L, McGorry PD (2005) Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull 31:672-696.
94. Paulus MP, Bakshi V, Geyer MA (1998) Isolation rearing affects sequential organization of motor behavior in post-pubertal but not pre-pubertal Lister and Sprague-Dawley rats. Behav Brain Res 94:271-280.
95. Pillai-Nair N, Panicker AK, Rodriguiz RM, Gilmore KL, Demyanenko GP, Huang JZ, Wetsel WC, Maness PF (2005) Neural cell adhesion molecule-secreting transgenic mice display abnormalities in GABAergic interneurons and alterations in behavior. J Neurosci 25:4659-4671.
96. Ragland JD, Gur RC, Glahn DC, Censits DM, Smith RJ, Lazarev MG, Alavi A, Gur RE (1998) Frontotemporal cerebral blood flow change during executive and declarative memory tasks in schizophrenia: a positron emission tomography study. Neuropsychology 12:399-413.
97. Rehn AE, Van Den Buuse M, Copolov D, Briscoe T, Lambert G, Rees S (2004) An animal model of chronic placental insufficiency: relevance to neurodevelopmental disorders including schizophrenia. Neuroscience 129:381-391.
98. Rosenberg DR, Lewis DA (1995) Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: a tyrosine hydroxylase immunohistochemical analysis. J Comp Neurol 358:383-400.
99. Sams-Dodd F, Lipska BK, Weinberger DR (1997) Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behavior in adulthood. Psychopharmacol 132:303-310.
100. Scherzer CR, Landwehrmeyer GB, Kerner JA, Counihan TJ, Kosinski CM, Standaert DG, Daggett LP, Velicelebi G, Penney JB, Young AB (1998) Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: hippocampus and cortex. J Comp Neurol 390:75-90.
101. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133-152.
102. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
103. Snyder SH (1973) Amphetamine psychosis: a model of schizophrenia mediated by catecholamines. Am J Psychiat 130:61-67.
104. Standaert DG, Landwehrmeyer GB, Kerner JA, Penney JB, Jr., Young AB (1996) Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Mol Brain Res 42:89-102.
105. Stevens JR (1992) Abnormal reinnervation as a basis for schizophrenia: a hypothesis. Arch Gen Psychiat 49:238-243.
106. Swerdlow NR, Lipska BK, Weinberger DR, Braff DL, Jaskiw GE, Geyer MA (1995) Increased sensitivity to the sensorimotor gating-disruptive effecs of apomorphine after lesions of medial prefrontal cortex of ventral hippocampus in adult rats. Psychopharmacology 122:27-34.
107. Thompson JL, Pogue-Geile MF, Grace AA (2004) Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophr Bull 30:875-900.
108. Tseng KY, O'Donnell P (2004) Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci 24:5131-5139.
109. Tseng KY, O'Donnell P (2006) Peri-adolescent maturation of dopamine modulation of interneuron activity in normal animals and in a developmental animal model of schizophrenia. Biol Psychiat 59:196S.
110. Tseng JY, O'Donnell P (2007) Dopamine modulation of prefrontal cortical interneurons changes during adolescence. Cereb Cortex 17:1235-1240.
111. van Kammen DP (1991) The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis. Psychological Medicine 21:881-895.
112. Vawter MP, Frye MA, Hemperly JJ, VanderPutten DM, Usen N, Doherty P, Saffell JL, Issa F, Post RM, Wyatt RJ, Freed WJ (2000) Elevated concentration of N-CAM VASE isoforms in schizophrenia. J Psychiatr Res 34:25-34.
113. Volk DW, Lewis DA (2002) Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 77:501-505.
114. Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA (2002) Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 12:1063-1070.
115. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997) Metbolic hyperfrontality and psychopathology in the ketamine model of psychosis using emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7:9-24.
116. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE (2003) Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8:592-610.
117. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE (2001) Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50:825-844.
118. Wenzel A, Villa M, Mohler H, Benke D (1996) Developmental and regional expression of NMDA receptor subtypes containing the NR2D subunit in rat brain. J Neurochem 66:1240-1248.
119. Williams K (1995) Pharmacological properties of recombinant N-methyl-D-aspartate (NMDA) receptors containing the epsilon 4 (NR2D) subunit. Neurosci Lett 184:181-184.
120. Woo TU, Pucak ML, Kye CH, Matus CV, Lewis DA (1997) Peripubertal refinement of the intrinsic and associational circuitry in monkey prefrontal cortex. Neuroscience 80:1149-1158.